上海宣泰医药科技股份有限公司自愿披露 关于公司产品拟中选国家药品接续采购的公告

Group 1 - The company, Shanghai Xuantai Pharmaceutical Technology Co., Ltd., has participated in the national organized procurement for the first to eighth batches of expiring agreements and has been proposed for selection in the continuation procurement for its product, ursodeoxycholic acid capsules [1] - The proposed selection will allow medical institutions to prioritize the use of the selected drug, ensuring the completion of the agreed procurement volume, which is expected to positively impact the company's sales scale, market share, and brand influence [1] Group 2 - The final selection data will be based on the results published by the continuation procurement office [1]